Impact of Early Discontinuation/Dose Modification of Venetoclax on Outcomes in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Haematologica
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The Impact of Early Discontinuation/Dose Modification of Venetoclax on Outcomes in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: Post-Hoc Analyses From the Phase III MURANO Study
Haematologica 2020 Dec 17;[EPub Ahead of Print], AR Mato, JP Sharman, JML Biondo, M Wu, Y Mun, SY Kim, K Humphrey, M Boyer, Q Zhu, JF SeymourFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.